NPPB and amyloidosis: The management of cardiac amyloid AL requires a multidisciplinary approach,involving hematology-oncology specialists as well as cardiologists given the factthat the degree of cardiac involvement is the most important prognostic factor inAL amyloidosis, and forms the basis of widely used staging systems [17].Circulating cardiac biomarkers, specifically NT-proBNP and cardiac troponin,correlate with myocardial amyloid burden and are the basis of those stagingsystems [17].